Related by context. All words. (Click for frequent words.) 80 Significant Increase 80 Quadruples 79 Dramatically Increases 79 Significantly Improves 78 Successfully Completed 78 Reduces Risk 78 More Than Doubles 78 Files Patent Application 78 Achieves Record 78 Helps Reduce 78 Achieves Milestone 78 Achieves Record Sales 78 Reports Positive 77 Significantly Reduces 77 Introduces Next Generation 77 Discontinues 77 Cuts Costs 77 Improves Survival 77 Shows Promise 77 Reconfirms 77 Awarded Patent 77 Dramatically Improves 76 Posts Strong 76 Helps Improve 76 Bodes Well 76 Submits Application 76 Expects Higher 76 Provides Updates 76 Provides Update Regarding 76 Reduces Debt 76 Outperforms 76 FDA Clears 76 Acquire Assets 76 Announces Discontinuation 76 Higher Than Expected 76 Amplifies 76 Provides Guidance 76 Receives Patent 76 Unveils Next Generation 76 Expands Capabilities 76 Introduces Breakthrough 76 Sees Continued 76 Sees Strong 76 Significantly Reduce 75 Achieves Significant 75 Strengthens Balance Sheet 75 Momentum Continues 75 Completes Successful 75 Unveils Expanded 75 More Than Doubled 75 Announces Successful Completion 75 Strengthens Position 75 Announce Collaboration 75 Boosts Productivity 75 Achieves Highest 75 Secures Financing 75 Achieves Positive 75 Announces FDA Clearance 75 Study Demonstrates 75 Commercializes 75 Completes Initial 75 Drops Sharply 75 Exceeds Expectations 75 Successfully Complete 75 Posts Record 75 Up Sharply 75 Temporarily Suspends 75 Successfully Tests 75 Q3 Loss Narrows 75 Delivers Next Generation 75 Jointly Announce 75 Unveils Breakthrough 75 Receives Positive 75 Jointly Develop 75 Completes Transition 75 Lower Than Expected 75 Develops Innovative 75 Diversifies 75 Q4 Loss Narrows 75 Continues Momentum 74 Develop Next Generation 74 Shares Soar 74 Doubles Size 74 Outlines Strategy 74 Obtains Approval 74 Nearly Triples 74 Profits Soar 74 Strengthens Its 74 Completes Expansion 74 Seeks Approval 74 Record Third Quarter 74 Doubles Capacity 74 Rises Sharply 74 Announces Initiation 74 Announce Availability 74 Generates Record 74 Shows Promising 74 Completes Tender Offer 74 Acquires Controlling Interest 74 Announce Completion 74 Net Loss Narrows 74 Speeds Up 74 Successfully Completes 74 Dramatic Increase 74 Q1 Loss Narrows 74 Report Indicates 74 Q3 Loss Widens 74 Surpasses Expectations 74 Improves Outcomes 74 Revolutionizes 74 Attains 74 Successfully Concludes 74 Report Analyzes 74 Unveils Revolutionary 74 Expands Scope 74 Board Authorizes 74 Jumps Higher 74 Introduces Enhanced 74 Results Confirm 74 Accelerates 74 Helps Ensure 74 Platform Enables 74 Announces Divestiture 74 Q4 Loss Widens 74 Study Confirms 74 Net Loss Widens 74 Improves Quality 74 Maintains Strong 74 Expand Relationship 74 Announce License Agreement 74 Expands Portfolio 74 Pending Acquisition 74 Offers Unprecedented 74 More Than Triples 74 Q1 Loss Widens 74 Study Indicates 74 4Q Profit Surges 74 Announces Favorable 74 Strengthens Leadership 74 Amends Agreement 74 Sees Higher 74 Completes Divestiture 74 Shares Climb 74 Expand Collaboration 74 Q4 Profit Plunges 74 Announces Immediate Availability 74 Posts Solid 74 Significantly Expands 74 Secures Funding 74 Holds Promise 74 Identifies Potential 74 Provides Comprehensive 74 Proves Successful 74 Files Patent 73 Finalizes Acquisition 73 Q4 Profit Surges 73 Validates 73 Further Strengthens 73 Shares Plummet 73 Refocuses 73 Ramping Up 73 Dramatically Reduces 73 Completes Purchase Of 73 Report Examines 73 Delivers Unprecedented 73 Announces Expanded 73 Stock Soars 73 Announce Collaboration Agreement 73 Q2 Loss Widens 73 Completes Patient Enrollment 73 IrelandRESEARCH AND MARKETS 73 Completes Installation 73 4Q Profit Slides 73 Posts Wider Loss 73 Beats Forecasts 73 Announces Revised 73 Launches Next Generation 73 Prove Effective 73 Introduces Innovative 73 Helps Prevent 73 Expands Capacity 73 Sees Significant 73 Fall Sharply 73 Accelerates Growth 73 Dips Slightly 73 Delivers Strong 73 Demonstrates Significant 73 Bulks Up 73 Files IND 73 Q2 Profit Surges 73 Announces Definitive Agreement 73 Profit Doubles 73 Closes Acquisition 73 Announces Commencement 73 Introduces Revolutionary 73 Q2 Loss Narrows 73 Streamlines Operations 73 Signs Licensing Agreement 73 Increases Capacity 73 Continues Aggressive 73 Improves Efficiency 73 Announce Receipt 73 4Q Loss Widens 73 Proven Effective 73 Updates Guidance 73 Receives Certification 73 Completes Enrollment 73 Hits Milestone 73 Percent Jump 73 Sign License Agreement 73 Forges Ahead 73 Announces Organizational Changes 73 Extends Reach 73 Announces Issuance 73 Updates Status 73 Profits Climb 73 Monetizes 73 Completes Integration 73 Earnings Decline 73 Outstrip 73 TriCo Bancshares Announces 73 Beat Estimates 73 Rise Sharply 73 Lowers Guidance 73 Helps Predict 73 Experiences Significant 73 Issues Guidance 73 Gets Approval 73 Files Shelf Registration Statement 73 Develop Novel 72 Begins Shipment 72 Drug Candidate 72 Achieves Profitability 72 Shifts Focus 72 Delivers Breakthrough 72 Acquires Assets 72 Builds Momentum 72 Significantly Improved 72 Increases Risk 72 Remains Committed 72 Wins Approval 72 Beats Expectations 72 Finalizes Agreement 72 Boosts Profit 72 Drop Sharply 72 Secures Additional 72 Profit Surges 72 Shares Surge 72 Q1 Profit Surges 72 Settle Patent Litigation 72 Q2 Profit Declines 72 Keeps Growing 72 Earnings Cheat Sheet 72 Receives Orphan Drug Designation 72 Amend Merger Agreement 72 Q1 Profit Declines 72 Enters Agreement 72 Announces Enhancements 72 Earnings Soar 72 Receives Favorable 72 Study Examines 72 Substantially Increases 72 Completes Conversion 72 Significantly Expand 72 Help Reduce 72 Growing Rapidly 72 Improves Productivity 72 Enlarges 72 Extends Offer 72 Tops Expectations 72 Edges Up 72 Study Identifies 72 Expedites 72 Releases Third Quarter 72 Ticks Higher 72 Third Quarter Profit Rises 72 Provide Comprehensive 72 Makes Strides 72 Ramps Up 72 Addresses Growing 72 Announces Publication 72 Announce Formation 72 Continues Steady 72 Fortifies 72 Re Affirms 72 Drug Fails 72 Shareholders Approve Merger 72 Profit Beats Estimates 72 Unveils Latest 72 Margin Expansion 72 Stock Plunges 72 Reduces Costs 72 Releases Next Generation 72 Increases Productivity 72 Gains Ground 72 Beefs Up 72 Above Estimates 72 Initiates Clinical Trial 72 Announces Resumption 72 Helps Boost 72 Well Positioned 72 Spins Out 72 2Q Profit Down 72 Provide Enhanced 72 FDA Okays 72 Announces Availability 72 Terminates Contract 72 Lowers Forecast 72 Tops Forecasts 72 Receives FDA Clearance 72 Formally Launches 72 Profit Soars 72 Moves Towards 72 Higher Margins 72 Misses Expectations 72 Summarizes 72 Raises Forecast 72 Announces Termination 72 Reduces Size 72 Q3 Profit Surges 72 Announce Merger Agreement 72 Submits Proposal 72 Could Trigger 72 1Q Profit Falls 72 Restructures Debt 72 Update# 72 Announces Licensing Agreement 72 Caution Urged 72 Finalizes Sale 72 Trims Loss 72 Outpaces 72 Signs Agreements 72 Announce Commencement 72 Bumps Up 72 Outlook Brightens 72 Closes Acquisition Of 72 Profit Misses Estimates 72 Losses Narrow 72 Launches Enhanced 72 Lowers Risk 72 Completes Merger With 72 Stabilizes 72 Unveils Groundbreaking 72 Introduces Powerful 72 Demonstrates Potential 72 2Q Profit Surges 72 Makes Headway 72 Holds Steady 72 Releases Latest 72 Could Revolutionize 72 Gathers Steam 72 Realigns 72 Raises Bid 72 Correlation Between 72 CFO Resigns 72 Spins Off 72 Shareholders Approve Acquisition 72 Sign Licensing Agreement 72 Slows Down 72 3Q Profit Drops 72 Provides Clarification 72 Confirms Commitment 72 Being Studied 72 Completes Acquisitions 72 Prolongs 72 Revenues Decline 72 Aquires 72 Q4 Profit Rises 72 Hits Lowest Level 72 Sees Positive 72 Help Improve 71 Keeps Climbing 71 Furthers 71 Halts Production 71 Lowers Costs 71 Extends Commitment 71 Completes Previously Announced 71 Successfully Completes Tender Offer 71 Anounces 71 Profits Decline 71 Ups Ante 71 Dramatically Expands 71 Record Fourth Quarter 71 Sees Rise 71 Shares Slump 71 Inches Up 71 Gaining Traction 71 Announces Restatement 71 Improve Quality 71 Reduces Cost 71 Successfully Tested 71 Revises Fourth Quarter 71 Announces Formation 71 Completes Restructuring 71 Explore Strategic Alternatives 71 Declines Slightly 71 Differentiates 71 Profit Slips 71 Sees Wider 71 Deliver Enhanced 71 Announces Cancellation 71 Introduces Expanded 71 Study Analyzes 71 Closes Sale 71 Sees Robust 71 Beats Estimates 71 4Q Profit Jumps 71 Jointly Offer 71 Signs Option Agreement 71 Update9 71 Finalize Agreement 71 Sign Definitive Agreement 71 Strengthens Commitment 71 Expert Joins 71 Q2 Profit Rises 71 Supercharges 71 Licenses Novel 71 Announces Signing 71 Demonstrates Commitment 71 Unveils Enhanced 71 Posts Higher 71 Unveils Innovative 71 4Q Profit Down 71 Plummets 71 Profit Dips 71 Proves Effective 71 Meets Estimates 71 Achieves Certification 71 Enters Joint Venture 71 Offers Affordable 71 Posts Lower 71 Reaffirms Commitment 71 Licenses Patents 71 Begins Shipping 71 Better Than Expected 71 1Q Profit Doubles 71 Finalizes Purchase 71 Quantifies 71 Board Unanimously Rejects 71 Delivers Improved 71 Q1 Profit Rises 71 Posts Profit 71 Launches Innovative 71 Capitalizes 71 Completes Purchase 71 Widely Used 71 Second Quarter Profit Rises 71 Pushes Ahead 71 4Q Profit Soars 71 Announce Agreement 71 Rapidly Growing 71 Up Slightly 71 Spur Growth 71 Outlook Dims 71 Posts 4Q 71 Deliver Next Generation 71 Reaches Record 71 Beats Forecast 71 Provides Preliminary 71 Remain Strong 71 Q4 Profit Declines 71 Increases Ownership 71 Consummates 71 Study Proves 71 1Q Profit Up 71 Q1 Adj 71 Plays Role 71 Gets FDA Clearance 71 Successfully Integrates 71 Exceeds Estimates 71 Lung Cancer Drug 71 Posts Third Quarter 71 Profit Increases 71 Demonstrates Improved 71 Profit Plunges 71 Solution Delivers 71 Receives Clearance 71 Sees Steady 71 Refines 71 Resumes Production 71 3Q Profit Jumps 71 Pave Way 71 Expand Into 71 Announces Positive 71 Remains Optimistic 71 Narrows 4Q Loss 71 3Q Loss Widens 71 3Q Profit Up 71 Posts 4Q Profit 71 Present Preclinical Data 71 Patent Issued 71 Down Slightly 71 Releases Second Quarter 71 Beat Expectations 71 Q2 Profit Plunges 71 Study Compares 71 Sees Continued Growth 71 Receives Favorable Ruling 71 1Q Profit Surges 71 Announces Preliminary 71 Extends Leadership 71 Univest Corporation Declares 71 Subsidiary Acquires 71 Bolsters 71 Results Indicate 71 3Q Profit Surges 71 Plans Buyback 71 Announces Successful 71 Successfully Deployed 71 Expands Relationship With 71 Q3 Profit Drops 71 Underpins 71 1Q Loss Narrows 71 Study Shows Benefits 71 Improve Efficiency 71 Rises Slightly 71 Exceed Estimates 71 Broadens Scope 71 Formalizes 71 Enters Into Agreement 71 Introduces Unique 71 Receives Approvals 71 Q2 Profit Drops 71 Lowest Level 71 Completes Sale Of 71 Achieves Record Growth 71 Gains Momentum 71 Officially Launches 71 Receives Milestone Payment 71 Narrows Loss 71 Revises Guidance 71 Subsidiary Expands 71 Marks Milestone 71 Becomes Largest 71 Renews Agreement 71 Lupus Drug 71 Restate Results 71 Posts Narrower Loss 71 Stays Neutral 71 Gains Traction 71 Inhibits 71 Loss Widens 71 Loss Narrows 71 1Q Profit Down 71 Announces Additions 71 Increases Quick Facts 71 Concludes Acquisition 71 Falls Sharply 71 Net Profit Drops 71 Outstrips 71 StockSource.us Reports 71 Increases Efficiency 71 Significantly Reduced 71 Boost Efficiency 71 Meets Expectations 71 Affirms Commitment 71 Announce Merger 71 Drags Down 71 Taps Into 71 Achieves Record Revenue 71 Achieves Unprecedented 71 Profit Sinks 71 Posts Loss 71 Sees Surge 71 Reveals Positive 71 Fifth Consecutive Year 71 Awarded Patents 71 Heightens 71 Raises Guidance 71 Slightly Lower 71 Announce Settlement 71 Lays Groundwork 71 Positions Itself 71 Commences Phase 71 Starts Shipping 70 Penetrates 70 Provides Updated 70 Extend Partnership 70 Sees Decline 70 Deliver Innovative 70 Renegotiates 70 Raises Outlook 70 Increases Size 70 Posts 2Q 70 Significant Reduction 70 Successfully Demonstrates 70 Misses Estimates 70 Provides Detailed 70 Recommences 70 Helps Identify 70 Poses Risks 70 Complete Merger 70 Study Links 70 Completes Financing 70 Helps Ease 70 Percent Rise 70 Ramps Up Production 70 Slightly Higher 70 Completes Merger 70 Q3 Profit Declines 70 2Q Profit Up 70 Record Levels 70 3Q Profit Falls 70 Announces Adjournment 70 Awarded Contracts 70 Showcases Innovative 70 Receives Notification 70 Provides Shareholder 70 Exercises Option 70 Multi Billion Dollar 70 Q1 Profit Soars 70 Costs Rise 70 Ups Dividend 70 Remains Steady 70 Obtains Patent 70 Announces Completion 70 Discloses 70 Extends Tender Offer 70 4Q Loss Narrows 70 Demand Grows 70 Nears Completion 70 Sees Increase 70 4Q Profit Falls 70 Delays Filing 70 Settles Charges 70 Updates Shareholders 70 Larger Than Expected 70 Exec Says 70 Weaker Than Expected 70 Announces Effective Date 70 2Q Profit Soars 70 Study Validates 70 Misses Estimate 70 Results Reflect 70 Seen Boosting 70 Enters Into Definitive Agreement 70 Receives Approval 70 Demystifies 70 Expands Availability 70 Newly Identified 70 Tool Helps 70 Immunomedics Announces 70 Deliver Powerful 70 Unveils Newest 70 Lowers Outlook 70 Subsidiary Completes 70 Announce Licensing Agreement 70 Announces Shareholder Approval 70 Underscores Commitment 70 Stronger Than Expected 70 Continues Climb 70 3Q Profit Rises 70 Plans Job Cuts 70 Sinks Lower 70 Down Sharply 70 4Q Profit Rises 70 Satisfies 70 Arthritis Drug 70 Stays Strong 70 Announces Expansion 70 Study Shows Significant 70 Appoints Seasoned 70 1Q Loss Widens 70 Elevates 70 Hikes Dividend 70 Misses Forecast 70 Announce Successful Completion 70 Announces Proposed 70 Q4 Profit Soars 70 Merger Creates 70 Deliver Integrated 70 Debuts Next Generation 70 Completes Private Placement 70 Eliminates Need 70 Q3 Profit Rises 70 Restate Financials 70 Announces Stockholder Approval 70 Subsidiary Receives 70 Expands Presence 70 Tremendous Growth 70 Loses Ground 70 Surges Ahead 70 Rise Slightly 70 Q3 Profit Soars 70 Slashes Price 70 Takeover Speculation 70 Reports Profitable 70 Quarterly Profit Rises 70 Abandons Plans 70 Boosts 70 Pumps Up 70 More Than Quadruples 70 Profits Plunge 70 Reverses Loss 70 3Q Loss Narrows 70 Posts 3Q Profit 70 Terminates Agreement 70 Results Exceed Expectations 70 Completes Sale 70 Sharply Higher 70 Significantly Improve 70 Analyst Downgrade 70 Continues Expansion 70 Subsidiary Wins 70 Outpace 70 Sees 1Q 70 Restructures 70 Implant Sciences Announces 70 Dramatically Increase 70 Seeks Buyer 70 Subsidiary Enters 70 Broadens Its 70 Earnings Climb 70 Expansion Continues 70 Revitalizes 70 Distinguishes 70 4Q Profit Slips 70 Reaches Milestone 70 Gets Upgraded 70 Shares Tumble 70 Unlocks 70 Completes Acquisition 70 Exec Sees 70 Profits Surge 70 Profit Climbs 70 Settle Patent Dispute 70 Multiplies 70 Q2 Adj 70 Report Suggests 70 Useful Tool 70 Confirms Significant 70 Presents Preclinical Data 70 2Q Profit Drops 70 Earnings Rise 70 Repositions 70 Fifth Consecutive 70 Remains Flat 70 Optimizes 70 4Q Profit Up 70 AnaSpec Introduces 70 Rate Climbs 70 Shareholders Approve 70 Forecast Raised 70 Rolled Out 70 Completes Reorganization 70 Profits Drop 70 Reports Sharply Higher 70 Sharpens Focus 70 Outshines 70 Completes Reverse Merger 70 Achieves Breakthrough 70 Sees Upside 70 Reaffirms Guidance 70 Ceases 70 Delivers Enhanced 70 Sees Opportunity 70 Underpin 70 Continues Commitment 70 Looks Promising 70 Strongly Linked 70 Sweetens Bid 70 Earns Top 70 Outweighs 70 Announces License Agreement 70 PPD Declares 70 Posts Quarterly 70 Profits Rise 70 Restate Financial 70 Successfully Closes 70 Update7 70 Deepens 70 Revenue Grows 70 Reduce Risk 70 4Q Profit Drops 70 Results Disappoint 70 Profit Triples 70 Announces Intent 70 Ups Stake 70 Protects Against 70 Completes Refinancing 70 1st Writethru 70 Shareholder Sues 70 Releases Enhanced 70 Delivers Powerful 70 FDA Warns 70 ANADIGICS Announces 70 Receives Authorization 70 Issues Clarification 70 Provides Update 70 Initiates Clinical Trials 70 Announces Receipt 70 Announces Early Termination 70 Announces Intention 69 Record Highs 69 Maximizes 69 Edges Higher 69 Rapidly Expanding 69 Enrolls First 69 Newly Acquired 69 Productivity Gains 69 Prolongs Survival 69 Profit Jumps 69 Investors Await 69 Report Identifies 69 Sixfold 69 Boosts Buyback 69 Meets Primary Endpoint 69 Develops Breakthrough 69 Gain Traction 69 Stockholders Approve Merger 69 Accelerate Adoption 69 Provides Unprecedented 69 Key Role 69 Could Save Lives 69 Settles Litigation 69 Potentially Fatal 69 Announces Acquisition 69 Reshapes 69 Q4 Profit Drops 69 Receives Conditional 69 Boosts Outlook 69 Migrates 69 Resolve Dispute 69 Surpass Expectations 69 Beats Views 69 Appoints Experienced 69 Could Exceed 69 Shows Promise Against 69 Magazine Recognizes 69 Extends Relationship 69 Launches Breakthrough 69 Extends Collaboration 69 Impairs 69 Drug Shows Promise 69 Buys Majority Stake 69 Actively Seeking 69 Tops Views 69 Announce Definitive Agreement 69 Earnings Surge 69 Stockholders Approve Acquisition 69 Study Reinforces 69 Q3 Profit Jumps 69 Boosts Dividend 69 Reaffirms Outlook 69 Reports Significantly Improved 69 Closes Buyout 69 Lauches 69 Ups Guidance 69 Solution Enables 69 Accelerate Commercialization 69 Collaborators Present 69 Gets Clearance 69 Submits NDA 69 Announces Dismissal 69 XPEL Announces 69 Randomized Trials 69 Outweigh 69 4th Qtr Profit Rises 69 Nearly Quadruples 69 3Q Profit Soars 69 Inks Deals 69 Analyst Predicts 69 Puts Focus 69 Initiates Enrollment 69 Regulators Approve 69 Helps Manage 69 Gives Boost 69 Terminate Merger Agreement 69 Narrows Guidance 69 Fine Tunes 69 Profits Jump 69 Launches Unique 69 Deliver Comprehensive 69 Expands Offerings 69 Seen Posting 69 Can Predict 69 3Q Profit Down 69 Expand Scope 69 Extend Relationship 69 Commences Operations 69 Withdraws Offer 69 Receives Unsolicited 69 Osteoporosis Drug 69 Celebrates Decade 69 Closes Previously Announced 69 Q2 Profit Soars 69 Deliver Breakthrough 69 Unexpectedly Falls 69 Delivers Exceptional 69 Voluntarily Withdraw 69 Enters Into Exclusive 69 Ink Deal 69 Relatively Low 69 2Q Profit Slides 69 Misses Views 69 Signs Merger Agreement 69 Cooperates 69 Could Prevent 69 1Q Profit Drops 69 Tests Confirm 69 Ups Bid 69 Growth Accelerates 69 Milestone Achieved 69 Analyst Upgrade 69 Bush Embraces Pause 69 Progresses 69 Improves Customer 69 Demonstrates Positive 69 Revenue Climbs 69 Confirms Receipt 69 Furthers Commitment 69 1Q Profit Slides 69 Solution Helps 69 Being Tested 69 Data Suggest 69 Commercialize 69 Boost Profits 69 Shrs Rise 69 Liquidates 69 Q3 Profit Climbs 69 Losses Widen 69 Multimillion Dollar 69 Test Detects 69 Identifies Key 69 Subsidiary Signs 69 Declares Increase 69 Announce Launch 69 Successfully Completes Acquisition 69 Slashes Prices 69 Epilepsy Drug 69 Enters Strategic 69 Receives Regulatory 69 Anticipates Record 69 Announces Profitable 69 Continues Rapid 69 Boosts Stake 69 Guides Above 69 Expand Capacity 69 Enters Definitive Agreement 69 Leadership Position 69 Expert Discusses 69 Solution Achieves 69 Releases Latest Version 69 Sees Increased 69 Expands Coverage 69 Reduces Pain 69 Report Cites 69 Reorganizes 69 Alert Technicals Showing Bearish 69 Virtually Unchanged 69 2Q Loss Narrows 69 Announces Refinancing 69 Tops Estimates 69 Announces Definitive Agreements 69 Profit Drops 69 Below Consensus 69 Signs Definitive Agreement 69 Tops Estimate 69 Pulls Down 69 Present Webinar 69 Better Manage 69 Rated Speculative Buy 69 Q1 Profit Jumps 69 Enables Faster 69 Achieve Significant 69 Patient Enrollment 69 2Q Profit Rises 69 Announces Presentation 69 Could Predict 69 Report Assesses 69 Successfully Launches 69 Japanese Stocks Climb 69 Fourth Consecutive Quarter 69 Launches Redesigned Website 69 Can Detect 69 Sixth Consecutive Quarter 69 Win Prestigious 69 Empowers Consumers 69 Reinforces Importance 69 Continues Slide 69 Could Harm 69 Q3 Profit Plunges 69 Planned Acquisition 69 Boosts Guidance 69 Delivers Comprehensive 69 FDA Approvals 69 Guides Inline 69 4Q Loss 69 Bearish Speculation 69 2Q Loss Widens 69 Receives Funding 69 Adds Depth 69 Celebrates Successful 69 Cites Positive 69 Provides Insights 69 Less Than Half 69 Smaller Than Expected 69 Profit Beats Expectations 69 Gathers Momentum